MoonLake Immunotherapeutics

MLTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$12.55

+$0.16 (+1.29%)

At close: Sep 21, 2026, 4:00 PM ET

$12.54

-$0.01 (-0.08%)

Pre-market: Sep 22, 2026, 6:40 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $1.04B

Enterprise Value $620.15M

Beta 1.04

Average Volume 1.16M

Shares Outstanding (Diluted) 73.92M

Shares Change YoY 16.8%

Institutional Ownership 88.46%

Exchange NASDAQ

ISIN KY61559X1045

Price Performance

Price Change 1M -20.0%

Price Change 3M -40.9%

Price Change 6M -30.4%

Price Change YTD 5.0%

Price Change 1Y -77.2%

Price Change 3Y -76.0%

Price Change 5Y 27.3%

1M CAGR (ann.) -31.3%

1Y CAGR (ann.) -75.8%

5Y CAGR (ann.) 4.6%

All-Time CAGR 2.9%

Valuation

PE Ratio -3.26

Forward PE N/A

PEG Ratio 0.10

Forward PEG -2.72

PS Ratio N/A

Forward PS 55.10

PB Ratio 2.47

P/FCF Ratio -4.69

P/Adj. FCF Ratio -4.25

P/OCF Ratio -4.11

EV/Sales N/A

EV/EBIT -2.44

EV/EBITDA -2.47

EV/FCF -2.75

Earnings Yield -30.7%

FCF Yield -21.3%

Adj. FCF Yield -23.5%

Financial Health

Net Cash $437.52M

Total Debt $101.53M

Cash & Short-Term Investments $537.03M

Total Assets $573.95M

Current Ratio 12.56

Quick Ratio 12.56

Debt / Equity Ratio 0.24

Debt / EBITDA -0.40

Debt / FCF -0.45

OCF / Debt -2.22

Interest Coverage -26.58

Altman Z-Score 2.48

Piotroski F-Score 1

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -10.3%

Returns

Return on Assets -45.9%

Return on Equity -82.7%

Return on Invested Capital -50.6%

Return on Capital Employed -50.8%

Return on Tangible Assets -45.9%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y -58.5%

EPS CAGR 5Y -37.1%

EPS CAGR 10Y N/A

FCF CAGR 3Y -52.6%

FCF CAGR 5Y -41.2%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 19

EPS Growth Next 3Y 29.5%

Revenue Growth Next 3Y N/A

Earnings Date N/A

EPS Estimate (next Q) N/A

EPS Growth Est (next Q) N/A

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $50

Price Target Upside 298.4%

Cash Flow

Operating Cash Flow $-225.18M

Free Cash Flow $-225.18M

Adj. Free Cash Flow $-248.38M

FCF Per Share -$3.05

OCF Per Share -$3.05

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-1.6M

Operating Income $-268.34M

EBITDA $-250.82M

Net Income $-263.67M

EPS (Diluted) -$3.85

Revenue / Employee N/A

Profit / Employee $-2.03M

Employees 130